World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 12 February 2013
Main ID:  ISRCTN35051281
Date of registration: 31/07/2009
Primary sponsor: Dr Suwelack Skin and Health Care AG (Germany)
Public title: Subdermal implantation of the collagen-elastin-matrix Matriderm® to improve profile and skin structure of degenerative changes in the midface region [Subkutaner einsatz der kollagen-elastin-matrix Matriderm® zur verbesserung von profil und hautstruktur bei degenerativen veränderungen des mittelgesichtes] SIMAMID II
Scientific title: Subdermal implantation of the collagen-elastin-matrix Matriderm® to improve profile and skin structure of degenerative changes in the midface region: a non-randomised single arm clinical trial
Date of first enrolment: May 15 2008
Target sample size: 30
Recruitment status: Completed/Not recruiting
URL:  http://isrctn.org/ISRCTN35051281
Study type:  Interventional
Study design:  Non-randomised single-arm clinical trial  
Countries of recruitment
Germany
Contacts
Name: Henrik  Menke
Address:  Klinik für Plastische-, Ästhetische- und Handchirurgie Schwerbrandverletztenzentrum Starkenburgring 66 63069 Offenbach Germany
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: Healthy adults aged 40 - 65 years, either sex
Exclusion criteria: 1. Severe allergies
2. Severe acute or chronic diseases
3. Skin infections


Age minimum:
Age maximum:
Gender:
Health Condition(s) or Problem(s) studied
Degenerative structure of profile and/or skin quality in the mid-face, caused by disease or ageing
Intervention(s)
Step 1: Subdermal laminar implantation of a collagen-elastin-matrix on the upper arm
Step 2: Subdermal laminar implantation of a collagen-elastin-matrix on the mid-face region

Skin biopsies (upper arm) before, 6 and 12 months post-operatively.
Primary Outcome(s)
Clinical outcome of mid-face region, measured at month 8 after step 1 (upper arm).
Secondary Outcome(s)
Clinical, histological and cutometric outcome upper arm, measured at month 14 after step 1 (upper arm).
Secondary ID(s)
DE/CA22/2-2008/KLP
Source(s) of Monetary Support
Dr Suwelack Skin and Health Care AG (Germany)
Secondary Sponsor(s)
N/A
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history